European Commission approves Mercadon Keytruda for assisted treatment of melanoma and lymph nodes in adult patients

recently, the cancer immunotherapy giant Merck and Co announced that the European Commission (EC) has approved the PD-1 tumor immunotherapy Keytruda (Chinese commodity name: Creeda, generic name: pembrolizumab, Pablo zumab, folk commonly known as K medicine), to assist in the treatment of the full excision of stage III melanoma and lymph nodes of adult patientsapproval also marks Keytruda's first assisted treatment indication approved in the European UnionFor melanoma, Keytruda has previously been approved for the treatment of advanced and metastatic melanomarelated researchthis approval is based on data from the critical Phase III clinical study EORTC1325/KEYNOTE-054The latest non-recurrent survival rate (RFS)analysis(http://data from Mercado, in collaboration with the European Cancer Research and Treatment Organization (EORTC), showed that Keytruda significantly longer RFS (HR-0.56,98%CI: 0.44-0.72, p.0001) in patients with high-risk stage III melanoma that had been removed compared to placebothe approval applies to all 28 EU member states and Iceland, Liechtenstein and NorwayKeytruda approved doses of 200 mg per 3 weeks until the disease recurs or is unacceptable, or lasts for up to one yearIn Europe, Keytruda is also approved as a single therapy for the treatment of advanced (non-rectructive or metastatic) melanoma in adult patients